Powered by: Motilal Oswal

News

Buy Metropolis Healthcare Ltd For Target Rs 1,610- JM Financial Institutional Securities Ltd Metropolis’ 1Q was tad below JMFe with loss of PPP revenues and network expansion costs partly offset by change in depreciation policy. Core business (ex-Covid, ex-PPP) revenue growth was 12%YoY and we expect this to sustain. Notably, PPP tender (NACO) expiry creates a void (INR 670mn in FY23) thereby optically subduing growth in FY24. New centres contributed ~6% to revenue but diluted margins by 110bps. Metropolis set up 6 labs in North and East and 118 collection centres across geogra...
Buy Metropolis Healthcare Ltd For Target Rs 1,610- JM Financial Institutional Securities Ltd
Buy Metropolis Healthcare Ltd For Target Rs 1,610- JM Financial Institutional Securities Ltd
Source: JM Financial Institutional Securities Ltd
4/08/2023 3:18:38 PM
Reduce Metropolis Healthcare For Target Rs. 1,400 - Yes Securities Result Synopsis Metropolis reported core business growth of 12% driven by 9% volume growth and ~3% increase in realization. Including PPP contract in the base and decline in covid, volumes declined 1% YoY. Company reiterated its lab and service centre expansion plans – additional 90 labs (to 270) and 1800 service centres (to 5,500) by 2025. While ~60% of the labs are coming in new geographies, management comments of first going after B2B business in these new geographies would pull d...
Reduce Metropolis Healthcare For Target Rs. 1,400 - Yes Securities
Reduce Metropolis Healthcare For Target Rs. 1,400 - Yes Securities
Source: Yes Securities Ltd
4/08/2023 12:30:35 PM
Buy Metropolis Healthcare For Target Rs.1,775 - JM Financial We interacted with METROHL’s management, the discussion provided us insights into current competitive trends, growth outlook and strategy. The competitive intensity has marginally abated although pressure still persists in the B2B segment. The company is contemplating price increases in the specialised segment which remains largely insulated from competition. The management’s revenue growth aspiration remains 15%+ (excluding PPP) with EBITDA margins expected to sustain current lev...
Buy Metropolis Healthcare For Target Rs.1,775 - JM Financial
Buy Metropolis Healthcare For Target Rs.1,775 - JM Financial
Source: JM Financial
1/04/2023 2:54:30 PM
Buy Metropolis Healthcare For Target Rs. 1,720 - Yes Securities Result Synopsis Metropolis exhibited a marginal miss on revenues and margin as Q3 sales declined 2.5% YoY and OPM fell ~100bps. Albeit, the internals were better than the headline print as B2C (~60% of core Metropolis sales) revenues grew 15% excluding Covid and allied tests; ex-Hitech and PPP contracts, sales up 13% - driven by healthy 9% volume growth and 3% price contribution. Margin were lower as network expansion (~12 labs and ~400 centers in 9m FY23) led to ~120bps impact. Metropoli...
Buy Metropolis Healthcare For Target Rs. 1,720 - Yes Securities
Buy Metropolis Healthcare For Target Rs. 1,720 - Yes Securities
Source: Yes Securities
23/03/2023 2:22:33 PM
Buy Metropolis Healthcare Ltd For Target Rs.1,933 - ICICI Securities Growth momentum continues in non-covid business Metropolis Healthcare’s (Metropolis) reported Q3FY23 performance was a mixed bag. Revenue declined 2.6% YoY (-5% QoQ) at Rs2.9bn (I-Sec: Rs2.8bn). Excluding Hi-Tech and government contract revenues, non-covid revenue grew ~13% YoY (+1,000bps from volume growth and +300bps from higher realisations). EBITDA margin contracted 160bps QoQ to 24.7%, driven by negative operational leverage (I-Sec: 26%). We remain positive on the company owing ...
Buy Metropolis Healthcare Ltd For Target Rs.1,933 - ICICI Securities
Buy Metropolis Healthcare Ltd For Target Rs.1,933 - ICICI Securities
Source: ICICI Securities Ltd
1/03/2023 1:47:11 PM
Healthcare stocks jump amid recent spike in cases of COVID-19 in some countries Shares of the healthcare service providers are trading higher, as Union Minister of Health and Family Welfare Mansukh Mandaviya chaired a high-level meeting to review the COVID-19 situation in India and preparedness of public health system for surveillance, containment and management of COVID-19 in view of the recent spike in cases of COVID-19 in some countries. Metropolis Healthcare is currently trading at Rs. 1370.80, up by 89.10 points or 6.95% from its previous closing of Rs. 1281.70 o...
Healthcare stocks jump amid recent spike in cases of COVID-19 in some countries
Healthcare stocks jump amid recent spike in cases of COVID-19 in some countries
Source: Accord Fintech
21/12/2022 3:50:25 PM
Prime Minister Narendra Modi to inaugurate 1st phase of Mumbai-Nagpur Super Expressway on Sunday Prime Minister Narendra Modi will inaugurate the Phase-I of the Mumbai-Nagpur Samruddhi Mahamarg (Super Communication Expressway) and take a tour of the new thoroughfare on Sunday, officials said here on Saturday. The 520 km-long Phase I is part of the total 701 km Super Expressway project linking the state capital Mumbai with Nagpur, passing through 10 districts. Being constructed at a cost of around Rs 55,000 crore, it is among the country's longest greenfield six-lane expressway ...
Prime Minister Narendra Modi to inaugurate 1st phase of Mumbai-Nagpur Super Expressway on Sunday
Prime Minister Narendra Modi to inaugurate 1st phase of Mumbai-Nagpur Super Expressway on Sunday
Source: IANS
10/12/2022 12:51:09 PM
Buy Metropolis Healthcare Ltd For Target Rs.1926 - ICICI Securities Growth continues in non-covid business Metropolis Healthcare’s (Metropolis) reported Q2FY23 performance was broadly in line with our estimates. Revenue remained flat YoY (+7.3% QoQ) at Rs3bn (ISec: Rs3.1bn) on a high base which had benefited from covid-related business. Non-covid revenue grew 15.8% YoY (3-year CAGR of 8.8%) led by steady recovery in footfalls and consolidation of HiTech. EBITDA margin grew 180bps QoQ to 26.3%, driven by operational leverage (I-Sec: 25%). We remain po...
Buy Metropolis Healthcare Ltd For Target Rs.1926 - ICICI Securities
Buy Metropolis Healthcare Ltd For Target Rs.1926 - ICICI Securities
Source: ICICI Securities Ltd
6/12/2022 2:34:49 PM
Sell Metropolis Healthcare Ltd For Target Rs.1475 - Centrum Broking Volume growth pressure persists Metropolis Healthcare (METROHL) reported Q2FY23 revenue of Rs3bn, flat on YoY and 7% QoQ, growth in non-Covid portfolio stood at 16% YoY. The company has witnessed ~11% decline in its core region of west & MMR, on account of heavy covid base last year which impacted revenue growth and decline in gross margin to 77.2%. During the quarter, METROHL saw 6% growth in revenue per patient, however, there was ~6% decline in patient volume YoY. EBITDA came at Rs7...
Sell Metropolis Healthcare Ltd For Target Rs.1475 - Centrum Broking
Sell Metropolis Healthcare Ltd For Target Rs.1475 - Centrum Broking
Source: Centrum Broking
15/11/2022 10:43:45 AM
Buy Metropolis Healthcare Ltd For Target Rs.1900 - Yes Securities Volumes key to sustainable growth Result Synopsis Metropolis clocked an inline quarter with core volume growth of 10% ex-Hitech and excluding government business (which has been lumpy and down YoY). Volume growth appears to be better than that of Dr Lal though uncertainty still looms large in the trajectory of footfall recovery over the next few quarters. Wellness share of revenues continues to inch up to 12% from 8% a year ago even as mix shifted somewhat towards routine tests in 2Q. M...
Buy Metropolis Healthcare Ltd For Target Rs.1900 - Yes Securities
Buy Metropolis Healthcare Ltd For Target Rs.1900 - Yes Securities
Source: Yes Securities Ltd
14/11/2022 12:12:11 PM
Buy Metropolis Healthcare Ltd For Target Rs1,760 -JM Financial Institutional Securities Ltd Focus shifts to 2Q Metropolis’ revenue miss dominated overall earnings miss which was primarily attributable to seasonality in West and South (1Q is the weakest). Gross margins improved c.30 bps YoY to 78% (JMFe: 77%) as Covid sales dwindled to INR 182 mn (6.5% of sales). Management guided that EBITDA margin blip (24.5% vs. JMFe: 25.9%) is transitory and should normalise to 25-26% sequentially as top-line improves. Non-Covid revenues grew 26% YoY driven by organic growth of 17% YoY a...
Buy Metropolis Healthcare Ltd For Target Rs1,760 -JM Financial Institutional Securities Ltd
Buy Metropolis Healthcare Ltd For Target Rs1,760 -JM Financial Institutional Securities Ltd
Source: JM Financial Institutional Securities Ltd
15/08/2022 10:53:42 AM
Buy Metropolis Healthcare Ltd For Target Rs.2,200 - Yes Securities Volume growth expectation intact Result Synopsis Metropolis reported healthy growth of 17% ex-Hitech in non Covid revenues which is driven by price mix followed by volumes. Including Hitech, revenue growth of 26% YoY in non Covid revenues appears strong but we would await signs of strength as non Covid base would be suppressed last year. So far, reckon pricing is holding up in 1Q despite the increased competitive intensity. Metropolis management did acknowledge it assessed several propo...
Buy Metropolis Healthcare Ltd For Target Rs.2,200 - Yes Securities
Buy Metropolis Healthcare Ltd For Target Rs.2,200 - Yes Securities
Source: Yes Securities Ltd
13/08/2022 11:03:49 AM
Buy Metropolis Healthcare Ltd For Target Rs.2,200 - Yes Securities Risk-reward appears favorable Result Synopsis Metropolis delivered a rather weak performance with revenue growth of ~5% YoY. The quarter was largely affected by lower government orders in non-covid space and the emergence of Omicron in the month of January. Acquisition of Ganesh Hitech and its growth ambitions in big cities like Mumbai and other should start reflecting in a few quarters. Margins have come down as acquisition, ESOP and other expenses are on the rise. Company plans to cla...
Buy Metropolis Healthcare Ltd For Target Rs.2,200 - Yes Securities
Buy Metropolis Healthcare Ltd For Target Rs.2,200 - Yes Securities
Source: Yes Securities Ltd
26/05/2022 10:24:21 AM
Metropolis Healthcare Q4 net profit down 33.08% at Rs 63.11 cr The company reported standalone net profit of Rs 63.11 crore for the quarter ended March 31, 2022 as compared to Rs 94.30 crore in the same period last year, registering a year-on-year decline of 33.08 per cent. Net revenue of the company declined moderately by 8.55 per cent at Rs 217.99 crore in January-March quarter of this fiscal as against Rs 238.36 crore in the corresponding period last year. During January-March quarter, operating expenses increased by 9.11 per cent to Rs 172.28 crore f...
Metropolis Healthcare Q4 net profit down 33.08% at Rs 63.11 cr
Metropolis Healthcare Q4 net profit down 33.08% at Rs 63.11 cr
Source: Dion Global Solutions Ltd
25/05/2022 11:27:46 AM
Add Metropolis Healthcare Ltd For Target Rs. 3,350 - Yes Securities Volume revival key to growth, margins Our view Metropolis missed on revenue and margin estimate on the back of lower specialized government contracts; Q4 expectation is for a rebound from a seasonally weak Q3 even as footfalls will remain affected due to Omicron scare in Jan. Expect FY23 to be a year of consolidation as company undertakes investment at HiTech (branding, scale up) which would dampen margin though reckon that would be a temporary phase with EBIDTA margin on track from FY2...
Add Metropolis Healthcare Ltd For Target Rs. 3,350 - Yes Securities
Add Metropolis Healthcare Ltd For Target Rs. 3,350 - Yes Securities
Source: Yes Securities Ltd
25/02/2022 3:25:58 PM
Buy Metropolis Healthcare Ltd For Target Rs.3,999 - Centrum Broking Digitalised expansion Metropolis Q3FY22 results were below estimates. The revenue was almost in-line meanwhile the costs reflected higher investment in digital initiative (would reflect in Q4 also) driving 3% impact, drop in covid realisation along with investments in labs and manpower. The quarter has one-time cost of Rs52mn related to ESOP and acquisition cost. We believe these investments would normalize as we go ahead and we maintain our margins expectations as the expansion and volume...
Buy Metropolis Healthcare Ltd For Target Rs.3,999 - Centrum Broking
Buy Metropolis Healthcare Ltd For Target Rs.3,999 - Centrum Broking
Source: Centrum Broking Ltd
15/02/2022 9:37:15 AM
Hold Metropolis Healthcare Ltd For Target Rs.3,190 - ICICI Securities Slow recovery in the non-COVID business Metropolis Healthcare (Metropolis) reported Q2FY22 performance was broadly in line with our estimates although recovery in the non-COVID business was slower than expected. Non-COVID revenue grew at 2-year CAGR of 7.9% driven by improvement in average realizations while volumes (no. of patients) were flat over the period. Overall, revenue grew 4.9% YoY to Rs3.0bn. EBITDA margin declined 170/150bps YoY/QoQ to 29.8%. Aggressive network expansion with fo...
Hold Metropolis Healthcare Ltd For Target Rs.3,190 - ICICI Securities
Hold Metropolis Healthcare Ltd For Target Rs.3,190 - ICICI Securities
Source: ICICI Securities Ltd
21/12/2021 10:51:37 AM
Quote on Fear of new covid virus variant in India will be positive Metropolis Healthcare Ltd By Mr. Yash Gupta, Angel One Ltd Below is quote on Fear of new covid virus variant in India will be positive Metropolis Healthcare Ltd by Mr. Yash Gupta, Equity Research Analyst, Angel One Ltd    We have seen a spike in new covid virus variant i.e Omicron in European countries, as of now more than 15 countries have Omicron covid cases in the world. As of now we haven’t seen cases on Omicron in India but several steps have been taken by authorities. World Health Organization ha...
Quote on Fear of new covid virus variant in India will be positive Metropolis Healthcare Ltd By Mr. Yash Gupta, Angel One Ltd
Quote on Fear of new covid virus variant in India will be positive Metropolis Healthcare Ltd By Mr. Yash Gupta, Angel One Ltd
Source: Angel One Ltd
29/11/2021 6:00:28 PM
Add Metropolis Healthcare Ltd For Target Rs.3,360 - Yes Securities Focus on volume revival Our view Metropolis has highlighted strong expansion plans till FY24 with addition of 90 labs and 1,800 centers across focus and non-focus regions to drive growth. Hitech acquisition would take time to pick up traction in terms of margin as first two years might be low on synergy benefits. We expect growth to rebound strongly in FY22 on a dampened base of last year and double-digit growth to continue in FY23 and FY24. Consolidated margins may remain slightly subd...
Add Metropolis Healthcare Ltd For Target Rs.3,360 - Yes Securities
Add Metropolis Healthcare Ltd For Target Rs.3,360 - Yes Securities
Source: Yes Securities Ltd
16/11/2021 10:32:49 AM
Quote on Metropolis Healthcare Limited by Mr. Yash Gupta, Angel One Ltd Below is quote on Metropolis Healthcare Limited by Mr. Yash Gupta, Equity Research Analyst, Angel One Ltd    Metropolis Healthcare acquisition of Hitech Diagnostics. Metropolis Healthcare Ltd acquisition of Hitech diagnostics for ₹636 crores, board of directors of the company clears the acquisition. Metropolis healthcare will acquire Hitech diagnostics for a cash consideration of ₹636 crores, earlier in Jan 2021 this deal was signed as a cash and ...
Quote on Metropolis Healthcare Limited by Mr. Yash Gupta, Angel One Ltd
Quote on Metropolis Healthcare Limited by Mr. Yash Gupta, Angel One Ltd
Source: Angel One Ltd
18/10/2021 3:47:22 PM
High Conviction Idea - Buy Metropolis Healthcare Ltd For Target Rs.3,422 - Religare Broking Geared for growth Incorporated in 1980, Metropolis Healthcare is one of the leading diagnostic players in India. It has a dominant share in the country’s western and southern regions. It offers a comprehensive range of 4,000+ clinical laboratory tests. It also offers analytical and supports services to clinical research organisations for their clinical research projects. Metropolis has spread its footprint across 19 states & 210 cities.   Investment Rationale * Diag...
High Conviction Idea - Buy Metropolis Healthcare Ltd For Target Rs.3,422 - Religare Broking
High Conviction Idea - Buy Metropolis Healthcare Ltd For Target Rs.3,422 - Religare Broking
Source: Religare Broking Ltd
5/10/2021 9:57:30 AM
Hold Metropolis Healthcare Ltd : Strong growth aided by covid related tests - ICICI Securities Hold Metropolis Healthcare Ltd For Target Rs.2,866 Strong growth aided by covid related tests Metropolis Healthcare (Metropolis) reported Q1FY22 performance better than estimates largely driven by covid related tests which contributed ~19% to revenue. Non-COVID revenue grew at 2-year CAGR of 8.8% but volumes (no. of patients) declined 1.7% as average realisation improved 9.0%. Overall, revenue grew 128% YoY to Rs3.3bn (I-Sec: Rs2.9bn). EBITDA margin was at 31.3% (I-Sec: 31.3%) aided ...
Hold Metropolis Healthcare Ltd : Strong growth aided by covid related tests - ICICI Securities
Hold Metropolis Healthcare Ltd : Strong growth aided by covid related tests - ICICI Securities
Source: ICICI Securities
24/09/2021 11:28:18 AM
Quote on Which stock should investors buy this GANESH CHATURTHI ? by Mr. Yash Gupta, Angel Broking Ltd Below is quote on Which stock should investors buy this GANESH CHATURTHI? by Mr. Yash Gupta, Equity Research Associate, Angel Broking Ltd    Since last year’s Ganesh Chaturthi stock markets have given very good returns to investors. Midcaps and Smallcaps have outperformed the border market, we suggest investors do not expect the same amount of returns that they would have got this year. We are suggesting these two stocks thi...
Quote on Which stock should investors buy this GANESH CHATURTHI ? by Mr. Yash Gupta, Angel Broking Ltd
Quote on Which stock should investors buy this GANESH CHATURTHI ? by Mr. Yash Gupta, Angel Broking Ltd
Source: Angel Broking Ltd
9/09/2021 4:36:37 PM
Add Metropolis Healthcare Ltd For Target Rs. 3,030 - Yes Securities Our view: Q1 FY22 was yet another disrupted quarter due to a severe COVID wave with COVID revenues at ~20% of revenues. We remove ~Rs900mn of HiTech revenues from FY22 sales as deal seems off the table – a direct fallout of the disruptive forces buffeting the sector. Uncertainty on the extent of rebound in non COVID patient footfalls would keep Q2 earnings (even as COVID recedes) under check; albeit, over the course of FY22/23, expect resumption of normalized 14‐15% footfall growth....
Add Metropolis Healthcare Ltd For Target Rs. 3,030 - Yes Securities
Add Metropolis Healthcare Ltd For Target Rs. 3,030 - Yes Securities
Source: Yes Securities
9/08/2021 10:03:32 AM
Add Metropolis Healthcare Ltd For Target Rs.2,687 - ICICI Securities Strong recovery with margin expansion Metropolis Healthcare (Metropolis) reported Q4FY21 performance better than estimates on margins and recovery in revenue growth was as per budgeted numbers provided earlier. Non-COVID volumes (no. of patients) grew 11.2% and average realisation (revenue/patient) improved 10.0% YoY. Overall, revenue grew 41.0% YoY to Rs2.9bn (I-Sec: Rs2.9bn). EBITDA margin improved 820bps to 33.0% (I-sec: 31.0%) led by higher realisation and controlled costs. COVID-19...
Add Metropolis Healthcare Ltd For Target Rs.2,687 - ICICI Securities
Add Metropolis Healthcare Ltd For Target Rs.2,687 - ICICI Securities
Source: ICICI Securities Ltd
2/07/2021 10:16:00 AM
Add Metropolis Healthcare Ltd For Target Rs.2,800 - Yes Securities Result Highlights * Healthy end to FY21 with 29% jump in patient visits and 42% revenue growth on pandemic impacted base of last year * More importantly, company appears confident of strong volume growth as seen in robust expansion plan in labs and service centres * No guidance given but expect patient volumes to clock ~23% cagr on FY21 base   Our view: Metropolis management refrained from giving any guidance for FY22 on back of continued uncertainty. Albeit, we expect reg...
Add Metropolis Healthcare Ltd For Target Rs.2,800 - Yes Securities
Add Metropolis Healthcare Ltd For Target Rs.2,800 - Yes Securities
Source: Yes Securities Ltd
31/05/2021 10:10:17 AM
Metropolis reported a very good set of numbers for Q4FY21 By Mr. Yash Gupta, Angel Broking Ltd Below are Quote on Metropolis reported a very good set of numbers for Q4FY21 by Mr. Yash Gupta Equity Research Associate, Angel Broking Ltd    Metropolis reported a very good set of numbers for Q4FY21. Metropolis healthcare limited reported total revenue from operations at ₹292 crores up by 42% YoY from ₹206 crores in Q4FY20. No of tests done up by 23% at 6.5Mn tests in this quarter Q4FY21. EBITDA for the quarter up by 86% at 97 cr...
Metropolis reported a very good set of numbers for Q4FY21 By Mr. Yash Gupta, Angel Broking Ltd
Metropolis reported a very good set of numbers for Q4FY21 By Mr. Yash Gupta, Angel Broking Ltd
Source: Angel Broking Ltd
28/05/2021 11:45:10 AM